Gilead Sciences/GILD

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada, Truvada for PrEP, Tybost, Veklury, Vemlidy, Viread, Vosevi, Yescarta and Zydelig. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, and Domvanalimab and zimberelimab, and seladelpar. Seladelpar shall be used for the treatment of primary biliary cholangitis (PBC), including pruritus. The Company operates in more than 35 countries.

Ticker

GILD

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Daniel O'Day

Employees

18,000

Headquarters

Foster city, United States

Gilead Sciences Metrics

BasicAdvanced
$80B
Market cap
178.73
P/E ratio
$0.36
EPS
0.22
Beta
$3.02
Dividend rate
4.79%
Dividend yield
$80B
0.21617
$87.87
$62.07
7M
$3.02
1.079
0.936
122.738
143.646
792.77%
13.67%
0.77%
2.51%
0.96%
178.731
2.917
4.566
19.669
3.86%
4.70%
4.79%
1.51%
-91.87%
3.17%
258.92%
3.32%

What the Analysts think about Gilead Sciences

Analyst Ratings

Majority rating from 32 analysts.
Hold

Gilead Sciences Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-62.38% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$6.7B
-6.02%
Net income
-$4.2B
-392.09%
Profit margin
-62.38%
-410.81%

Gilead Sciences Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 11.59%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$1.34
$2.29
$1.72
-$1.32
-
Expected
$1.64
$1.92
$1.76
-$1.49
$1.59
Surprise
-18.42%
19.44%
-2.24%
-11.59%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market open

Upcoming events

Jun
27
Gilead Sciences
Dividend·Payment
$0.77
Per share

FAQs

What’s the current market cap for Gilead Sciences stock?

Gilead Sciences (GILD) has a market cap of $80B as of June 17, 2024.

What is the P/E ratio for Gilead Sciences stock?

The price to earnings (P/E) ratio for Gilead Sciences (GILD) stock is 178.73 as of June 17, 2024.

Does Gilead Sciences stock pay dividends?

Yes, the Gilead Sciences (GILD) stock pays dividends to shareholders. As of June 17, 2024, the dividend rate is $3.02 and the yield is 4.79%. Gilead Sciences has a payout ratio of 792.77% on a trailing twelve-month basis.

When is the next Gilead Sciences dividend payment date?

The next Gilead Sciences (GILD) dividend payment is scheduled for June 27, 2024.

What is the beta indicator for Gilead Sciences?

Gilead Sciences (GILD) has a beta rating of 0.22. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Gilead Sciences stock

Buy or sell Gilead Sciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing